At3g07290 Antibody

What is At3g07290 and why is it important in plant research?

At3g07290 encodes a pentatricopeptide repeat-containing protein that localizes to mitochondria in Arabidopsis thaliana . This protein belongs to a family involved in RNA processing within organelles, particularly important in post-transcriptional regulation. Understanding At3g07290's function contributes to our knowledge of plant mitochondrial gene expression regulation and organelle biogenesis. The protein has been identified in transcriptomic studies examining meristem development in Arabidopsis , suggesting potential roles in developmental processes. Antibodies against this protein enable researchers to investigate its expression patterns, subcellular localization, and potential protein-protein interactions.

What applications are At3g07290 antibodies validated for?

Commercial At3g07290 antibodies are primarily validated for ELISA and Western blotting (WB) applications . These validation methods ensure the antibody can specifically identify the target antigen. For rigorous research, it's advisable to perform additional validation in your specific experimental system. According to the International Working Group for Antibody Validation, antibodies should be validated using at least one of the five conceptual pillars: genetic strategies, orthogonal strategies, independent antibody strategies, tagged protein expression, or immunocapture followed by mass spectrometry . For At3g07290 antibodies specifically, validation data typically includes Western blot analysis demonstrating specific binding to the target protein at the expected molecular weight.

How should I store and handle At3g07290 antibodies for optimal performance?

At3g07290 antibodies should be stored at -20°C or -80°C upon receipt . Repeated freeze-thaw cycles should be avoided as they can lead to antibody degradation and loss of binding activity. Commercial At3g07290 antibodies are typically supplied in a storage buffer containing 50% glycerol, 0.01M PBS (pH 7.4), and 0.03% Proclin 300 as a preservative . When working with the antibody, aliquoting into single-use volumes is recommended to prevent degradation from repeated freezing and thawing. Prior to use, thaw antibodies slowly on ice and centrifuge briefly to collect the solution at the bottom of the tube. For diluted working solutions, prepare them fresh and use within 24 hours for optimal results.

How specific is the At3g07290 antibody and what cross-reactivity might I expect?

Commercial At3g07290 antibodies are primarily designed to react with Arabidopsis thaliana proteins . Cross-reactivity with homologous proteins in closely related plant species might occur, particularly within the Brassicaceae family. When applying these antibodies to non-Arabidopsis samples, preliminary validation is essential. The specificity of an antibody depends on the immunogen used for its production - in this case, recombinant Arabidopsis thaliana At3g07290 protein . To assess potential cross-reactivity, bioinformatic analysis comparing sequence homology between At3g07290 and related proteins in your species of interest can provide initial insights. Following this, experimental validation through Western blotting with appropriate positive and negative controls is necessary to confirm specificity in your experimental system.

How can I validate the specificity of At3g07290 antibody in my experimental system?

Validating antibody specificity is crucial for reliable results. For At3g07290 antibody, implement a multi-layered validation approach:

• Genetic validation: Use knockout or knockdown lines of At3g07290 in Arabidopsis as negative controls . CRISPR-Cas9 or RNAi approaches can generate these lines if not commercially available. A significant reduction in signal in these lines compared to wild-type plants provides strong evidence of specificity.

• Orthogonal validation: Compare protein expression detected by the antibody with mRNA levels measured by RT-qPCR or RNA-seq data . Correlation between protein and transcript levels across different tissues or conditions supports antibody specificity.

• Independent antibody validation: If available, use multiple antibodies targeting different epitopes of At3g07290 and compare their detection patterns . Consistent results between different antibodies increase confidence in specificity.

• Recombinant protein controls: Include purified recombinant At3g07290 protein as a positive control in Western blots to confirm the correct band size .

• Preabsorption test: Preincubate the antibody with excess antigen before application in your assay - this should significantly reduce or eliminate specific signals .

What are the optimal conditions for Western blotting with At3g07290 antibody?

For successful Western blot detection of At3g07290:

• Sample preparation: Extract total protein from plant tissue using a buffer optimized for membrane proteins, such as one containing 50mM Tris-HCl (pH 7.5), 150mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, and protease inhibitors . For mitochondrial proteins like At3g07290, consider enriching mitochondrial fractions through differential centrifugation.

• Protein denaturation: Heat samples at 95°C for 5 minutes in Laemmli buffer containing SDS and β-mercaptoethanol to ensure complete denaturation.

• Gel electrophoresis: Use 10-12% SDS-PAGE gels for optimal separation of the At3g07290 protein.

• Transfer conditions: Transfer proteins to PVDF membranes (preferred over nitrocellulose for their higher protein binding capacity) at 100V for 60-90 minutes in standard transfer buffer (25mM Tris, 192mM glycine, 20% methanol).

• Blocking: Block membranes with 5% non-fat dry milk or 3-5% BSA in TBST (TBS with 0.1% Tween-20) for 1 hour at room temperature.

• Primary antibody incubation: Dilute At3g07290 antibody according to manufacturer's recommendations (typically 1:1000 to 1:2000) in blocking buffer and incubate overnight at 4°C.

• Washing: Wash membranes thoroughly with TBST (4 × 5 minutes) to reduce background.

• Secondary antibody: Incubate with appropriate HRP-conjugated secondary antibody (anti-rabbit IgG for most commercial At3g07290 antibodies) at 1:5000-1:10000 dilution for 1 hour at room temperature .

• Detection: Use enhanced chemiluminescence (ECL) substrate and optimize exposure times based on signal intensity.

What controls should I include when working with At3g07290 antibody?

A robust experimental design requires appropriate controls:

• Positive control: Include wild-type Arabidopsis tissue samples known to express At3g07290, preferably from tissues with reported high expression levels based on transcriptomic data .

• Negative control: Use tissue from At3g07290 knockout or knockdown plants if available . Alternatively, use tissues where expression is expected to be minimal based on published expression data.

• Loading control: Include detection of housekeeping proteins (e.g., actin, tubulin, or GAPDH) to ensure equal loading across samples.

• Secondary antibody-only control: Omit primary antibody to assess non-specific binding of the secondary antibody.

• Blocking peptide control: If available, include a sample where the primary antibody has been pre-incubated with the immunizing peptide to confirm signal specificity .

• Molecular weight marker: Include a reliable protein ladder to confirm the expected molecular weight of At3g07290.

• Cross-species control: If working with non-Arabidopsis samples, include Arabidopsis samples as reference for comparing band patterns.

How can I use At3g07290 antibody for co-immunoprecipitation (Co-IP) studies?

Co-immunoprecipitation with At3g07290 antibody can reveal protein-protein interactions:

• Antibody selection: Ensure the At3g07290 antibody has been validated for immunoprecipitation applications. Polyclonal antibodies often perform better for Co-IP than monoclonal antibodies due to their recognition of multiple epitopes .

• Cell lysis and protein extraction: Use a gentle, non-denaturing lysis buffer (e.g., 20mM Tris-HCl pH 7.5, 150mM NaCl, 1mM EDTA, 1% NP-40, 5% glycerol) supplemented with protease inhibitors to preserve protein-protein interactions . For mitochondrial proteins like At3g07290, consider isolating mitochondria first before lysis.

• Pre-clearing: Incubate the lysate with protein A/G beads alone to reduce non-specific binding.

• Antibody binding: Incubate the pre-cleared lysate with At3g07290 antibody (typically 1-5μg per mg of total protein) overnight at 4°C with gentle rotation.

• Immunoprecipitation: Add protein A/G beads and incubate for 1-4 hours at 4°C. For rabbit polyclonal At3g07290 antibodies, protein A beads generally work well .

• Washing: Perform stringent washing (at least 4-5 washes) with lysis buffer to remove non-specifically bound proteins.

• Elution and analysis: Elute bound proteins with SDS sample buffer, separate by SDS-PAGE, and analyze by Western blotting or mass spectrometry to identify interacting partners.

• Validation: Confirm interactions with reciprocal Co-IP and alternative methods such as yeast two-hybrid or proximity ligation assays.

• Controls: Include IgG control (same species as the At3g07290 antibody) and input samples in parallel to assess non-specific binding and enrichment efficiency.

Can At3g07290 antibody be used to study protein localization through immunofluorescence?

While commercial At3g07290 antibodies are primarily validated for ELISA and Western blot , adapting them for immunofluorescence requires:

• Tissue preparation: Fix plant tissue in 4% paraformaldehyde, embed in paraffin or resin, and prepare thin sections (5-10μm). Alternatively, use cultured plant cells or protoplasts for easier visualization.

• Antigen retrieval: Perform heat-induced epitope retrieval in citrate buffer (pH 6.0) if necessary to expose epitopes potentially masked during fixation.

• Permeabilization: Treat samples with 0.1-0.5% Triton X-100 to allow antibody access to intracellular antigens.

• Blocking: Block with 3-5% BSA or normal serum from the same species as the secondary antibody for 1 hour at room temperature.

• Primary antibody incubation: Apply diluted At3g07290 antibody (starting with 1:100-1:500 dilutions) and incubate overnight at 4°C in a humidified chamber.

• Secondary antibody: Use fluorophore-conjugated secondary antibodies (e.g., Alexa Fluor) against rabbit IgG at 1:500-1:1000 dilution .

• Counterstaining: Include organelle markers such as MitoTracker for mitochondria to confirm co-localization with At3g07290.

• Controls: Include samples with secondary antibody only, pre-immune serum, and competitive blocking with immunizing peptide if available.

• Optimization: Systematically test different fixation methods, antibody dilutions, and incubation times to optimize signal-to-noise ratio.

• Confocal microscopy: Use confocal laser scanning microscopy with appropriate filter sets to visualize fluorescent signals and assess co-localization.

How can I use At3g07290 antibody to study protein expression across developmental stages?

To track At3g07290 expression during plant development:

• Developmental sampling: Collect Arabidopsis tissues at defined developmental stages from day 7 to 16 after germination, as this period shows dynamic changes in meristem development .

• Protein extraction: Use a consistent extraction protocol across all samples, preferably one optimized for mitochondrial proteins.

• Quantitative Western blotting: Perform Western blots with careful control of protein loading amounts and inclusion of internal standards for normalization.

• Densitometric analysis: Quantify band intensities using software like ImageJ, and normalize to loading controls.

• Statistical validation: Analyze biological replicates (minimum n=3) to establish statistical significance of expression patterns.

• Correlation with transcriptomics: Compare protein expression patterns with available RNA-seq data from similar developmental stages .

• Tissue-specific analysis: Consider using laser-capture microdissection to isolate specific tissues for more precise localization of expression.

• Validation with independent methods: Confirm expression patterns using RT-qPCR, RNA in situ hybridization, or reporter gene constructs.

Table 1: Experimental design considerations for developmental expression studies with At3g07290 antibody

Why might I observe multiple bands when using At3g07290 antibody in Western blot?

Multiple bands in Western blot can result from several factors:

• Post-translational modifications: At3g07290 might undergo modifications like phosphorylation or glycosylation, resulting in molecular weight shifts. Treat samples with phosphatases or glycosidases to determine if modifications account for the additional bands.

• Alternative splicing: Check databases for reported splice variants of At3g07290 that might produce proteins of different sizes.

• Protein degradation: Improve sample preparation by adding protease inhibitors, keeping samples cold, and reducing processing time. Compare fresh samples with stored ones to identify degradation patterns.

• Cross-reactivity: The antibody may recognize related proteins with similar epitopes. Validate specificity using knockout/knockdown approaches and peptide competition assays .

• Incomplete denaturation: Ensure complete protein denaturation by heating samples sufficiently in sample buffer containing adequate SDS and reducing agents.

• Antibody concentration: High antibody concentrations can increase non-specific binding. Perform a dilution series to determine the optimal concentration that maximizes specific signal while minimizing background.

• Sample overloading: Excessive protein loading can result in smearing and artificial bands. Optimize protein loading with a gradient of concentrations.

• Membrane stripping and reprobing: If membranes were stripped and reprobed, residual signals from previous antibodies might appear as additional bands.

How can I address high background issues when using At3g07290 antibody?

High background can significantly impair data interpretation. To reduce background:

• Optimize blocking: Test different blocking agents (BSA, non-fat dry milk, casein) and concentrations (3-5%) to determine which most effectively reduces non-specific binding for your specific antibody.

• Antibody dilution: Use the manufacturer's recommended dilution as a starting point, then optimize through a dilution series (e.g., 1:500, 1:1000, 1:2000, 1:5000).

• Incubation conditions: Incubate primary antibody at 4°C overnight instead of at room temperature to improve specific binding. For secondary antibodies, shorter incubation times (1 hour) at room temperature are typically sufficient.

• Washing protocol: Increase the number and duration of washing steps with TBST or PBST. Use fresh, filtered buffers and ensure thorough washing between antibody incubations.

• Buffer additives: Add 0.05-0.1% Tween-20 to antibody dilution buffers to reduce non-specific binding. For particularly problematic backgrounds, consider adding 5% normal serum from the same species as the secondary antibody.

• Membrane choice: PVDF membranes generally have lower background than nitrocellulose but require methanol activation before use.

• Secondary antibody cross-reactivity: Use secondary antibodies specifically absorbed against plant proteins to reduce cross-reactivity with endogenous plant immunoglobulins.

• Filter antibody solutions: Centrifuge diluted antibody solutions briefly or filter through a 0.22μm filter to remove aggregates that can contribute to background.

• Reduce exposure time: When using chemiluminescent detection, optimize exposure times to maximize signal-to-noise ratio.

How can I interpret conflicting results between different detection methods using At3g07290 antibody?

When facing discrepancies between different assays:

• Method-specific epitope accessibility: The target epitope might be accessible in denatured conditions (Western blot) but masked in native conditions (immunoprecipitation). Consider using alternative antibodies recognizing different epitopes.

• Validation strategy: Apply the "five pillars" approach to antibody validation :

  • Genetic validation: Compare results using At3g07290 knockout or knockdown lines

  • Orthogonal validation: Compare antibody-based results with orthogonal methods like mass spectrometry

  • Independent antibody validation: Use multiple antibodies targeting different epitopes

  • Tagged protein expression: Compare detection of endogenous protein with tagged versions

  • Immunocapture-MS: Analyze the proteins captured by the antibody using mass spectrometry

• Context-dependent protein associations: At3g07290 might engage in different protein complexes depending on cellular conditions, affecting epitope accessibility.

• Technical variables: Systematically evaluate technical variables that differ between methods, including sample preparation, protein conformation, and detection sensitivity.

• Quantitative comparison: Where possible, perform quantitative analyses using standard curves and reference materials to enable direct comparison between methods.

• Experimental design: Design experiments that can reconcile conflicting results, such as using a series of mutants with varying expression levels of At3g07290 to establish a relationship between protein abundance and signal intensity across methods.

What approaches can resolve issues with antibody aggregation affecting At3g07290 detection?

Antibody aggregation can compromise experimental outcomes. To address this:

• Storage conditions: Store antibodies according to manufacturer recommendations, typically at -20°C or -80°C with minimal freeze-thaw cycles . For working solutions, store at 4°C for short periods only.

• Centrifugation before use: Briefly centrifuge antibody solutions (10,000 × g for 5 minutes) before use to pellet any aggregates.

• Filtration: Filter diluted antibody solutions through a 0.22μm filter to remove aggregates before application.

• Buffer optimization: Ensure the antibody dilution buffer maintains proper pH (typically 7.2-7.4) and ionic strength. Adding 0.05% sodium azide can prevent microbial growth in stored antibody solutions.

• Carrier proteins: Add BSA (0.1-1%) to diluted antibody solutions to prevent non-specific adsorption to tubes and surfaces.

• Detergent addition: Low concentrations of non-ionic detergents (0.05-0.1% Tween-20) can reduce aggregation and non-specific binding.

• Temperature control: Avoid rapid temperature changes when handling antibodies, and allow refrigerated antibodies to equilibrate to room temperature before opening to prevent condensation.

• Quality assessment: Periodically assess antibody quality through simple binding assays if stored for extended periods.

• Specialized approaches: For persistent aggregation issues, techniques like size-exclusion chromatography can be used to isolate non-aggregated antibody fractions .

How can quantitative methods be applied to At3g07290 antibody studies?

Advanced quantitative approaches enhance research rigor:

• Absolute quantification: Develop a quantitative Western blot method using purified recombinant At3g07290 protein to create standard curves for absolute quantification.

• Sedimentation velocity analytical ultracentrifugation (SV-AUC): This technique can be used to analyze protein-antibody interactions under native conditions and provide quantitative binding parameters .

• Surface plasmon resonance (SPR): Determine binding kinetics and affinity constants between At3g07290 antibody and its target antigen through real-time, label-free detection of molecular interactions .

• Multiplex analysis: Develop multiplex assays to simultaneously quantify At3g07290 alongside other proteins of interest in the same biological context.

• Single-cell approaches: Adapt At3g07290 antibody for single-cell protein analysis technologies to investigate cell-to-cell variability in protein expression.

• Statistical validation: Implement rigorous statistical approaches, including power analysis to determine appropriate sample sizes and advanced statistical methods for analyzing complex data sets.

• Digital image analysis: Use computational approaches to quantify immunofluorescence or immunohistochemistry signals for spatial analysis of At3g07290 expression.

What are the most promising directions for future At3g07290 antibody development?

Future antibody technologies could enhance At3g07290 research:

• Engineered antibody fragments: Develop single-chain variable fragments (scFvs) or antigen-binding fragments (Fabs) against At3g07290 for applications requiring smaller probe size and better tissue penetration .

• Nanobodies: Single-domain antibodies derived from camelid antibodies offer advantages for recognizing conformational epitopes and accessing restricted cellular compartments.

• Cross-species reactive antibodies: Develop antibodies recognizing conserved epitopes in At3g07290 homologs across plant species to facilitate comparative studies.

• Conformation-specific antibodies: Generate antibodies that specifically recognize different conformational states or post-translationally modified forms of At3g07290.

• Multiplexed detection systems: Develop antibody panels for simultaneous detection of At3g07290 and interacting partners or related proteins within the same pathway.

• Integration with CRISPR technologies: Combine antibody-based detection with CRISPR-based genome editing to correlate At3g07290 protein expression with genetic modifications.

• Environmental sensing applications: Explore the potential of At3g07290 antibodies in biosensor development for monitoring plant responses to environmental stresses.

• Structural biology applications: Use antibodies as crystallization chaperones to facilitate structural determination of At3g07290 protein complexes.